Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with H. pylori. Methods: This study was conducted on 100 patients diagnosed with H. pylori by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of H. pylori was assessed by a stool antigen test 4 weeks after therapy. Results: Eradication of H. pylori infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (P<0.022). Conclusion: Simvastatin significantly improves the H. pylori eradication rate.
Keywords: clarithromycin resistance; eradication of H. Pylori; simvastatin; standard triple therapy.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Sequential Therapy Versus Standard Triple-Drug Therapy for Helicobacter Pylori Eradication: A Prospective Randomized StudyH Seddik et al. Eur J Clin Pharmacol 69 (9), 1709-15. PMID 23695545. - Randomized Controlled TrialBased on our results, we conclude that for eradication of H. pylori infection, the 10-day sequential therapy is more effective than the standard triple therapy and is equ …
Randomised Clinical Trial: Simvastatin as Adjuvant Therapy Improves Significantly the Helicobacter Pylori Eradication Rate--A Placebo-Controlled StudyW Nseir et al. Aliment Pharmacol Ther 36 (3), 231-8. PMID 22646167. - Randomized Controlled TrialIn this randomised clinical trial simvastatin as adjuvant to standard therapy improves significantly the H. pylori eradication rate.
Supplementing Vitamins C and E to Standard Triple Therapy for the Eradication of Helicobacter PyloriM Sezikli et al. J Clin Pharm Ther 37 (3), 282-5. PMID 21740452. - Randomized Controlled TrialAdding vitamins C and E to standard triple therapy increases the eradication rate of H. pylori. Vitamins C and E may increase the eradication rate via increasing the effe …
Eradication of Helicobacter Pylori With Triple Therapy: An Epidemiologic Analysis of Trends in Turkey Over 10 YearsA Kadayifci et al. Clin Ther 28 (11), 1960-6. PMID 17213016. - ReviewRates of H. pylori eradication with the triple-therapy regimen decreased in Turkey over the 10-year period studied. In an era of increasing clarithromycin use, the effect …
Optimum Duration of Regimens for Helicobacter Pylori EradicationY Yuan et al. Cochrane Database Syst Rev (12), CD008337. PMID 24338763. - ReviewIncreasing the duration of PPI-based triple therapy increases H. pylori eradication rates. For PCA, prolonging treatment duration from 7 to 10 or from 10 to 14 days is as …